Morgan Stanley analyst Matthew Harrison noted that the head of the National Institute for Allergy and Infectious Disease, Dr. Anthony Fauci, indicated that dosing of the first patient for Moderna's COVID-19 vaccine candidate would be "soon," adding that he would expect an announcement from the NIAID around first patient dosing. Fauci had originally indicated he did not expect first patient dosing until late April, so this update is about 1.5 months ahead of schedule, said Harrison, who has an Overweight rating and $30 price target on Moderna.
Stock futures saw modest early gains following Wednesday's mixed action and Thursday's holiday closure as investors returned for a shortened Black Friday session. The Nasdaq was... To see the rest of the story go to thefly.com. See Story Here